A recent study suggests that using gadopiclenol at half the standard gadolinium dose provides comparable, and in some cases superior, contrast enhancement in breast MRI compared to full-dose gadobutrol. These findings could lead to adjusted imaging protocols for high-risk patients, while simultaneously minimizing cumulative gadolinium exposure.
Breast MRI is a vital tool for detecting and monitoring breast cancer, especially for early identification in individuals with BRCA1 or BRCA2 gene mutations. Dynamic contrast-enhanced MRI utilizes gadolinium-based contrast agents to highlight vascularized tissue, aiding radiologists in lesion detection with high sensitivity, even in dense breast tissue. However, concerns persist regarding cumulative gadolinium deposition and potential environmental contamination, particularly for patients with impaired kidney function.
Gadobutrol, a widely used macrocyclic chelate, binds gadolinium for safe passage and elimination by the kidneys. Gadopiclenol, a next-generation agent, boasts higher T1-relaxivity, enabling strong tissue contrast at a reduced dose.
In the study, gadopiclenol demonstrated higher absolute enhancement across all assessed regions, with breast parenchyma contrast increasing by approximately 25% in later phases compared to full-dose gadobutrol. Radiologists rated image quality and diagnostic confidence as equal or slightly better for gadopiclenol in most instances. These results indicate that high-relaxivity contrast agents can maintain or improve diagnostic performance while decreasing gadolinium exposure.
Limitations include the study's retrospective, single-center design and the use of paired scans taken up to two years apart. Further multicenter studies are needed to validate these findings and assess cost-effectiveness of reduced-dose protocols.